DMD and Duchenne muscular dystrophy: Initial reports from this trial have been highly encouraging, with a mean level of exon skipping of 53% after three biweekly 10 mg/kg doses in the first three DMD patients treated, although dystrophin protein levels were negligible (Tillinger et al. 2023).